ライフサイエンスコーパス: colony-stimulating factor

1 ponses (Th1, Th2, and granulocyte-macrophage colony-stimulating factor).

2 atments except CTLA-4/granulocyte macrophage colony-stimulating factor.

3 sis factor alpha, and granulocyte-macrophage colony-stimulating factor.

4 and possibly also for granulocyte-macrophage colony-stimulating factor.

5 r-like phenotype with granulocyte-macrophage colony-stimulating factor.

6 ancement of IL-10 and granulocyte-macrophage colony-stimulating factor.

7 osis factor-alpha and granulocyte macrophage colony-stimulating factor.

8 of responsiveness to granulocyte-macrophage colony-stimulating factor.

9 necrosis factor inhibitors, and granulocyte colony-stimulating factors.

10 (CSF-1R) signaling and its ligands IL-34 and colony stimulating factor 1 (CSF-1).

11 Viral-mediated knockdown of neuronal colony stimulating factor 1 (CSF1) was used to modulate

12 ranscription factor Wilms' Tumor 1 (WT1) and colony stimulating factor 1 (CSF1).

13 he ventral microglial reaction by removal of colony stimulating factor 1 from motoneurons or in CCR2

14 central nervous system (CNS) is dependent on colony stimulating factor 1 receptor (CSF-1R) signaling

15 tor (MCSF) secreted by cancer cells binds to colony stimulating factor 1 receptor (CSF1-R) on macroph

16 Macrophage-targeted inhibition of the colony stimulating factor 1 receptor (CSF1R) by immunoth

17 lly following removal via treatment with the colony stimulating factor 1 receptor (CSF1R) inhibitor P

18 l of chronically activated microglia using a colony stimulating factor 1 receptor (CSF1R) inhibitor,

19 Colony stimulating factor 1 receptor (CSF1R) plays key r

20 nate immune cells in brain, are dependent on colony stimulating factor 1 receptor (CSF1R) signaling f

21 it is observed that sustained inhibition of colony stimulating factor 1 receptor (CSF1R) using a CSF

22 f macrophages, including microglia, requires Colony Stimulating Factor 1 Receptor (CSF1R), a gene pre

23 to target TAM, and an antibody-neutralizing colony stimulating factor 1 receptor (CSF1R).

24 t leukoencephalopathy caused by mutations in colony stimulating factor 1 receptor (CSF1R).

25 Elimination of microglia using the colony stimulating factor 1 receptor antagonist PLX5622

26 a mouse model of alcohol dependence using a colony stimulating factor 1 receptor inhibitor (PLX5622)

27 show that treatment with the pharmacological colony stimulating factor 1 receptor inhibitor PLX5622 s

28 Treating MIA offspring by colony stimulating factor 1 receptor inhibitors induces

29 ut adulthood, and reveals a potent effect of colony stimulating factor 1 receptor inhibitors on the c

30 n of microglia using PLX3397, which inhibits colony stimulating factor 1 receptor, ameliorated this d

31 Colony-stimulating factor 1 (CSF-1) and interleukin (IL)

32 ted with gamma interferon (IFN-gamma) DNA or colony-stimulating factor 1 (CSF-1) DNA prior to ocular

33 Colony-stimulating factor 1 (CSF-1), the cytokine acting

34 clear that alloantibody can, in concert with colony-stimulating factor 1 (CSF-1)-dependent donor macr

35 ly suppresses OC differentiation by limiting colony-stimulating factor 1 (CSF-1)-dependent proliferat

36 n neutralizing antibodies against macrophage colony-stimulating factor 1 (CSF1 or MCSF) or F4/80.

37 l nerve injury induced de novo expression of colony-stimulating factor 1 (CSF1) in injured sensory ne

38 mples, we found sensitivity to inhibition of colony-stimulating factor 1 (CSF1) receptor (CSF1R), a r

39 , locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1).

40 dent macrophages (Mac(AIR)) that depend upon colony-stimulating factor 1 and are sustained by local p

41 In response to liver injury, colony-stimulating factor 1 drives early monocyte-mediat

42 e induced in the female mice and deletion of colony-stimulating factor 1 from sensory neurons, which

43 nocycline, and depletion of microglia with a colony-stimulating factor 1 inhibitor, indicated that mi

44 tumour-to-tumour heterogeneity, response to colony-stimulating factor 1 receptor (CSF-1R) blockade a

45 ing skeletal development through analysis of colony-stimulating factor 1 receptor (csf1r) function in

46 Colony-stimulating factor 1 receptor (CSF1R) inhibition

47 -PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor,

48 Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling f

49 Most macrophages require colony-stimulating factor 1 receptor (CSF1R), but some m

50 y ligand that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R), the expres

51 nent in tumors and are normally dependent on colony-stimulating factor 1 receptor (CSF1R), we treated

52 exposed to RSD, microglia were eliminated by colony-stimulating factor 1 receptor antagonism (PLX5622

53 In contrast, colony-stimulating factor 1 receptor blockade diminished

54 mHTT) accumulation, and early death, through colony-stimulating factor 1 receptor inhibition (CSF1Ri)

55 hed in mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.

56 microglia (99%) by administering the CSF1R (colony-stimulating factor 1 receptor) antagonist PLX5622

57 results of studies inhibiting the macrophage colony-stimulating factor 1 receptor,whereas the CD11b(+

58 y autosomal dominant mutations in the CSF1R (colony-stimulating factor 1) gene.

59 etween interleukin 1 receptor antagonist and colony-stimulating factor 1, colony-stimulating factor 2

60 fibrosis, illustrating the critical role of colony-stimulating factor 1-dependent monocyte/macrophag

61 The cytokine colony stimulating factor-1 (CSF-1) acts as an important

62 Colony stimulating factor-1 (CSF-1) promotes placentatio

63 Microglial depletion with the colony stimulating factor-1 receptor (CSF-1R) inhibitor

64 We found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks gl

65 nd function of mononuclear phagocytes is the colony stimulating factor-1 receptor (CSF-1R), which has

66 liferation is regulated by many factors, but colony stimulating factor-1 receptor (CSF1R) has emerged

67 Interestingly, colony stimulating factor-1 receptor (CSF1R) is signific

68 osynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative

69 f monocytes and, together with low levels of colony-stimulating factor-1 (CSF-1), inhibit their diffe

70 the macrophage attractant and growth factor colony-stimulating factor-1 (CSF-1).

71 microRNA in breast cancer cells by limiting colony-stimulating factor-1 (CSF1)-dependent recruitment

72 t targeting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade i

73 The colony-stimulating factor-1 receptor (CSF-1R) kinase reg

74 ession and can be targeted via inhibition of colony-stimulating factor-1 receptor (CSF-1R) to regress

75 tiation is mediated by signaling through the colony-stimulating factor-1 receptor (CSF-1R) which is n

76 n of myeloid cells through the inhibition of colony-stimulating factor-1 receptor (CSF1Ri) to monitor

77 Our results suggest that colony-stimulating factor-1 receptor inhibition may be a

78 This study evaluated the effect of the colony-stimulating factor-1 receptor inhibitor PLX5622 o

79 We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 t

80 id cell responses via inducing chemokine and colony stimulating factor 2 (CSF2) expression in kidney

81 antagonist and colony-stimulating factor 1, colony-stimulating factor 2 and interleukin 17F, without

82 ulating factor; genetic mutations in CSF2RA (colony-stimulating factor 2 receptor alpha-subunit), MAR

83 We hypothesized that thrombin-induced colony-stimulating factor-2 (CSF-2) in decidual cells tr

84 day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mug/m(2) per dose) subcut

85 Here we identify that colony stimulating factor 3 (CSF3), released during acut

86 in 6, interleukin 10 receptor alpha subunit, colony stimulating factor 3 receptor and toll-like recep

87 a high prevalence (>80%) of mutations in the colony-stimulating factor 3 receptor (CSF3R).

88 interleukin-6, tumour necrosis factor-a and colony-stimulating factor 3), and antiinflammatory marke

89 Colony-stimulating factor-3 receptor (CSF3R)-T618I is a

90 o 28-day cycles); or intravenous granulocyte colony-stimulating factor (300 mug/m(2) per day or 5 mug

91 00 mg/m(2)/dose on days 1-5; and granulocyte-colony stimulating factor 5 ug/kg/dose, days 1-5 and day

92 nterleukin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alone or combin

93 rophages in adulthood and raised granulocyte-colony stimulating factor and neutrophil counts/activity

94 partially due to its induction by macrophage colony-stimulating factor and downregulation by IFN-gamm

95 macrophages easily in vitro with macrophage colony-stimulating factor and human serum.

96 e.g. decreased responsiveness to granulocyte colony-stimulating factor and increased leukemogenesis).

97 ecrete cytokines (eg, granulocyte-macrophage colony-stimulating factor and interferon-gamma) critical

98 reduced responses to granulocyte-macrophage colony-stimulating factor and markedly decreased activit

99 of microglial chemokines, such as macrophage-colony-stimulating factor and monokine induced by interf

100 by the expression of granulocyte-macrophage colony-stimulating factor and the C-X-C chemokine recept

101 angerin and CD1a with granulocyte-macrophage colony-stimulating factor and transforming growth factor

102 ssue necrosis factor, granulocyte-macrophage colony-stimulating factor) and cytolytic degranulation p

103 a, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at 18 hours.

104 regulation of cytokines including macrophage colony-stimulating factor, and 3-fold increased osteocla

105 y stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-reactive protein at enr

106 BAL fluid IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels.

107 roxidase, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels.

108 ecrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and granzyme B), and they wer

109 ladribine, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone), or reduced

110 scular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.

111 Interferon-gamma and granulocyte-macrophage colony-stimulating factor are requisite factors in the t

112 = 432), PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo

113 ymethylcellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favoura

114 Recent reports have identified hematopoietic colony-stimulating factors as important regulators of tu

115 re prevented by interleukin-1 or granulocyte colony-stimulating factor blockade, revealing remarkable

116 B-cell depletion and granulocyte-macrophage colony-stimulating factor blockade.

117 Neutralizing granulocyte-colony stimulating factor blocked susceptibility to dise

118 stained expression of granulocyte-macrophage colony-stimulating factor by renal tubular cells, which

119 ilized with cyclophosphamide and granulocyte colony-stimulating factor, collected by peripheral blood

120 fter stimulation with granulocyte-macrophage colony-stimulating factor, compared with cells transfect

121 , influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.

122 Colony-stimulating factor (CSF)-1 and interleukin (IL)-3

123 ructural remodeling of neurons via increased colony-stimulating factor (CSF)-1 in the medial PFC.

124 nnate immunity-related markers calprotectin, colony-stimulating factor (CSF)-1, macrophage migration

125 g the expression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells.

126 on signals from the receptor for macrophage colony-stimulating factor, CSF1R.

127 enhanced bacterial replication in macrophage colony-stimulating factor-differentiated macrophages mor

128 rophages more than in granulocyte-macrophage colony-stimulating factor-differentiated macrophages.

129 hematopoietic stress, including granulocyte colony-stimulating factor, do not increase the mutation

130 ocyte chemotactic protein-3, and granulocyte-colony stimulating factor during the acute phase (p < 0.

131 rt that in tumor-bearing mice the macrophage colony-stimulating factor elevates the myeloid cell leve

132 In NK cell-deficient mice, granulocyte colony-stimulating factor-expanded neutrophils show an i

133 service, meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed melioidosis seps

134 nd that the neuroactive cytokine granulocyte-colony stimulating factor (G-CSF) alters cocaine reward

135 ective effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem cell factor (

136 rk from our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuroactive cytok

137 ation, with a five-day course of granulocyte colony stimulating factor (G-CSF) as the most common reg

138 Using a granulocyte-colony stimulating factor (G-CSF) receptor knockout mous

139 Following VSG, circulating granulocyte-colony stimulating factor (G-CSF) was increased in mice,

140 A, beta2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three monoclonal

141 -activating protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocyte macrophag

142 ammatory factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL-11, IL-1alp

143 transplant (tx), tumor (tm), and granulocyte-colony stimulating factor (g-csf)-expanded MDSCs or depl

144 se tissue, in part via increased granulocyte-colony stimulating factor (G-CSF).

145 hood due to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these effects are rev

146 ecules (interleukine (IL)-1beta, granulocyte colony stimulating factor (G.CSF), IL-13, IL-6, IL-12, i

147 ify the proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) as a key medi

148 runcation mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administration early i

149 tment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration.

150 ation of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4 d

151 myeloproliferation was driven by granulocyte colony-stimulating factor (G-CSF) and administration of

152 on and migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemokine receptor

153 essed the safety and efficacy of granulocyte colony-stimulating factor (G-CSF) and haemopoietic stem-

154 uced severely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nitric oxide (N

155 the concurrent administration of granulocyte colony-stimulating factor (G-CSF) enhanced RT-mediated a

156 inherent disadvantages of using granulocyte colony-stimulating factor (G-CSF) for hematopoietic stem

157 essed the efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in steroid nonresponde

158 Granulocyte colony-stimulating factor (G-CSF) is a regulator of neut

159 Granulocyte colony-stimulating factor (G-CSF) is used clinically to

160 ttractive protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in the amniotic

161 te globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves beta-cell fu

162 rpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patient

163 nterpart, 2 designs bound to the granulocyte colony-stimulating factor (G-CSF) receptor and exhibited

164 ation of the Csf3r gene, reduced granulocyte colony-stimulating factor (G-CSF) receptor levels, atten

165 revented HSPC mobilization after granulocyte colony-stimulating factor (G-CSF) stimulation.

166 lood circulation by the cytokine granulocyte colony-stimulating factor (G-CSF) through complex mechan

167 xpression in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen, due to its

168 d significantly higher levels of granulocyte colony-stimulating factor (G-CSF), interleukin 1alpha (I

169 MIP-1beta, granulocyte colony-stimulating factor (G-CSF), interleukin-12/23 (IL

170 8, gamma interferon (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), monocyte chemoattract

171 syndrome are often treated with granulocyte colony-stimulating factor (G-CSF), which can increase ne

172 Nociceptor neurons drive granulocyte colony-stimulating factor (G-CSF)-induced HSC mobilizati

173 at appears in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated donors (GDs) c

174 a standard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

175 three different ligands based on granulocyte colony-stimulating factor GCSF homo-dimeric derivatives

176 Flt3 ligand (FL) (days 1-10) and granulocyte colony-stimulating factor (GCSF) (days 4-10).

177 Human granulocyte colony-stimulating factor (GCSF) is a well-known cytokin

178 ents with incomplete response to granulocyte colony-stimulating factor (GCSF) treatment decreased ser

179 ndomized to 1) ATG and pegylated granulocyte colony-stimulating factor (GCSF), 2) ATG alone, or 3) pl

180 IL)-4, IL-6, IL-8, IL-10, IL-15, granulocyte colony-stimulating factor (GCSF), MCP-1, tumor necrosis

181 We also show that granulocyte colony-stimulating factors (GCSF and GM-CSF) enhance swa

182 utoantibodies against granulocyte-macrophage colony-stimulating factor; genetic mutations in CSF2RA (

183 Recently, granulocyte-macrophage colony stimulating factor (GM-CSF) has been identified a

184 ed the involvement of granulocyte-macrophage colony stimulating factor (GM-CSF) in nociceptor activat

185 e mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally ma

186 d with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF) was presented in the

187 ating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-18, monocyt

188 or alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 6 (IL-6)

189 immunogenic levels of granulocyte-macrophage colony stimulating factor (GM-CSF), through deregulation

190 ends on production of granulocyte macrophage-colony stimulating factor (GM-CSF), which recruits and m

191 n-gamma (IFN-gamma) and granulocyte monocyte colony stimulating factor (GM-CSF).

192 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) is a pro-inf

193 onse, as decreases in granulocyte-macrophage colony-stimulating factor (GM-CSF) (6.6-fold), RANTES (1

194 The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) (encoded by Csf2) is

195 terleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (oAd) and DCs for sus

196 dermally with 200 mug granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant or 200 mug G

197 ry mediators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and C-C motif chemoki

198 died, others, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL

199 ence of the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL

200 e with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix metallopep

201 by cancer cell-derived granulocyte-monocyte colony-stimulating factor (GM-CSF) and occurred in a Sta

202 stigated neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potential strate

203 IFN-gamma, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as transcript

204 ed productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF) by central nervous sy

205 CL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhance the immun

206 nate gels loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) for concentrating den

207 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improving walking

208 Granulocyte-macrophage colony-stimulating factor (GM-CSF) has many more functio

209 g evidence shows that granulocyte macrophage colony-stimulating factor (GM-CSF) has progression-promo

210 es in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) in vitro.

211 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multipotent cyto

212 st that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in the EDM-TTF-

213 Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by T helper

214 IL)-1beta that drives granulocyte-macrophage colony-stimulating factor (GM-CSF) production by CD4(+)

215 T cells that secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) promote graft-versus-

216 ing factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) resembled in vivo inf

217 piratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which stim

218 by the disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling and can be

219 Granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling in astrocy

220 c fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts locally and

221 Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growt

222 interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor

223 Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly produced by M

224 kin-4 (IL-4), but not granulocyte-macrophage colony-stimulating factor (GM-CSF), signaling.

225 delivers the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the Toll-like-recept

226 neurotrophins and the granulocyte-macrophage colony-stimulating factor (GM-CSF)-CC-chemokine ligand 1

227 tumor cells inhibited granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced CD103(+) DC d

228 RORgammat, CCR6, and granulocyte macrophage colony-stimulating factor (GM-CSF).

229 c hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

230 nduced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF).

231 epithelium to produce granulocyte-macrophage colony-stimulating factor (GM-CSF).

232 nt with IL-3, IL-5 or granulocyte-macrophage colony-stimulating factor (GM-CSF).

233 esized that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist cytokine l

234 interleukin-6 [IL-6], granulocyte-macrophage colony-stimulating factor [GM-CSF], CCL3, CCL5, and CXCL

235 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-4, and MIP-1alpha

236 g assay, we show that granulocyte-macrophage colony-stimulating factor (GMCSF) is a key CRS-promoting

237 ls of IL-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony

238 mide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated

239 ased the secretion of granulocyte macrophage-colony stimulating factor, IL-12, -13, and -15, which wa

240 m, and adjunctive treatment with granulocyte colony-stimulating factor in 1998.

241 and the pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of preexisting

242 atopoietic cytokines (especially granulocyte colony-stimulating factor) in shortening the duration of

243 Treatment with a high dose of granulocyte colony-stimulating factor increases neutrophil productio

244 e (interleukin-4 plus granulocyte macrophage-colony stimulating factor)-induced activation of Rac1, i

245 r of nuclear factor kappaB ligand/macrophage colony-stimulating factor induction of nuclear factor of

246 d chemokines, such as granulocyte macrophage colony-stimulating factor, interferon-gamma, interleukin

247 els of cytokines (interleukin 6, granulocyte colony-stimulating factor, interleukin 1 receptor antago

248 by T-helper 17 cells (granulocyte-macrophage colony-stimulating factor, interleukin [IL]17A, IL17F, I

249 omatography of recombinant human granulocyte colony stimulating factor is demonstrated.

250 Granulocyte-macrophage colony-stimulating factor is a potential therapeutic tar

251 days in-vitro in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator

252 ary outcome was the production of macrophage-colony stimulating factor (M-CSF) and tumor necrosis fac

253 Macrophage colony stimulating factor (M-CSF) was implicated as a co

254 es of macrophages stimulated with macrophage colony-stimulating factor (M-CSF) and granulocyte-M-CSF

255 ar factor kappa B ligand (RANKL), macrophage colony-stimulating factor (M-CSF) and transforming growt

256 r of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as well as BMSC CM fro

257 -Fms) and hyper-responsiveness to macrophage colony-stimulating factor (M-CSF) in bone marrow macroph

258 that monocytes differentiated by macrophage colony-stimulating factor (M-CSF) or granulocyte macroph

259 of hematopoietic progenitors with macrophage colony-stimulating factor (M-CSF) resulted in mTORC1-dep

260 macrophage glucose metabolism by macrophage colony-stimulating factor (M-CSF; inflammation resolving

261 IFNgamma IL-10, GzB, granulocyte macrophage colony-stimulating factor, macrophage inflammatory prote

262 First, macrophage colony stimulating factor (MCSF) secreted by cancer cell

263 fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus cytarabine,

264 imary functional human MEPs from granulocyte colony-stimulating factor-mobilized peripheral blood and

265 se of mismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripheral blood ste

266 of immune cells contained within granulocyte colony-stimulating factor-mobilized peripheral blood ste

267 x lasso glycoprotein, granulocyte-macrophage colony-stimulating factor, modeling both reducing and ox

268 s factor (TNF) alpha, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant 1, m

269 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutralization inhibited DC an

270 tion of neutrophil functions via granulocyte colony-stimulating factor neutralization significantly d

271 fector Akt induced by granulocyte-macrophage colony-stimulating factor or interleukin-4.

272 weeks, plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signali

273 gand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus contributing

274 PEGylated recombinant human granulocyte colony stimulating factor (pegfilgrastim) is used clinic

275 Filgrastim, an analog for granulocyte colony-stimulating factor produced by recombinant DNA te

276 pregulated numbers of granulocyte-macrophage colony-stimulating factor-producing B cells within peric

277 ron-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subsequent mala

278 reduced responses to granulocyte-macrophage colony-stimulating factor, providing an additional mecha

279 that activating mutations in the granulocyte colony stimulating factor receptor (CSF3R), cooperate wi

280 r [IL-3R], IL-5R, and granulocyte-macrophage colony stimulating factor receptor) signaling in the abs

281 mutations in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR) in approxima

282 acid binding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase

283 receptor family (CSF3R/CSF3) and macrophage colony-stimulating factor receptor family (CSF1R/IL34/CS

284 tes is primarily governed by the granulocyte colony-stimulating factor receptor family (CSF3R/CSF3) a

285 eporter mice (mice expressing the macrophage colony-stimulating factor receptor GFP transgene through

286 eptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CAL

287 nd II cytokine receptors, except granulocyte colony-stimulating factor receptor, which supported only

288 Granulocyte-macrophage colony-stimulating factor-receptor-alpha expression patt

289 Granulocyte-macrophage colony-stimulating factor-receptor-alpha was predominant

290 d more surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD2

291 ing recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as a model drug, th

292 Second, colony stimulating factors, secreted by cancer cells, po

293 (C-C motif) ligand 9, granulocyte-macrophage colony-stimulating factor, soluble tumor necrosis factor

294 SCs was controlled by granulocyte-macrophage colony-stimulating factor, through the activation of the

295 ar calcium levels and granulocyte macrophage-colony-stimulating factor, tumor necrosis factor alpha,

296 eks, 10 mg daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1000 mg o

297 s of IFN-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly reduced, wh

298 Therapeutic colony-stimulating factors were associated with a 1.42-d

299 1r locus encodes the receptor for macrophage colony-stimulating factor, which controls the proliferat

300 r hypersensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell dysplasia an